FDA accepts Sanofi lixisenatide NDA for review
The acceptance of the lixisenatide NDA filing follows the 1 February 2013 European Commission approval of lixisenatide in the European Union (EU), according to Sanofi. The application for
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.
GCLP status indicates that the operation standards of the contract research division are compliant with the British Association of Research Quality Assurance standards. Epistem contract research division co-founder
Precision’s next-generation genome engineering technologies, collectively known as the Directed Nuclease Editor or DNE, aids in making the tools and resulting cells possible. Precision chief scientific officer and